CEBPA and acute myeloid leukemia: A comparison of the 88 KMT2A/MLL-R+ pediatric AML cases with 71 cases of FLT3-ITD+/NPM1+/CEBPA+ pediatric AML cases exhibited 34 differentially expressed probesets, of which 26 probesets were significantly upregulated in the KMT2A/ MLL-R+ subset.